David A. Carlson

TL;DR: Fasnall, a thiophenopyrimidine selectively targeting FASN through its co-factor binding sites, showed potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly when combined with carboplatin.

TL;DR: Takinib is a potent and selective TAK1 inhibitor that induces apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast cancer and is an attractive starting point for the development of inhibitors that sensitize cells to T NF-α-induced cell death, with general implications for cancer and autoimmune disease treatment.

TL;DR: HS-72 is well-tolerated, showing bioavailability and efficacy, inhibiting tumor growth and promoting survival in a HER2+ model of breast cancer, suggesting an ideal starting point for a new generation of anticancer drugs targeting Hsp70i.

TL;DR: A fluorescence linked enzyme chemoproteomic strategy (FLECS) for the rapid identification of inhibitors for any element of the purinome and a selective pyrazolo[3,4-d]pyrimidinone (HS38) that inhibits DAPK1 and ZIPK in an ATP-competitive manner at nanomolar concentrations are developed.

TL;DR: It is demonstrated that circulating HSP90α is upregulated in IPF patients in correlation with disease severity and believed that the specific inhibition of extracellular HSP 90α is a promising therapeutic strategy to reduce pro-fibrotic signalling in IPf.